Table 3.
Prognostic factors for progression-free survival (PFS) and overall survival (OS) of ovarian clear cell carcinoma patients
| Variables | 5 year-PFS % | p valuea | p valueb | HR (95%CI) | 5 year-OS % | p valuea | p valueb | HR (95%CI) |
|---|---|---|---|---|---|---|---|---|
| Endometriosis | 0.001 | 0.295 | 0.013 | 0.677 | ||||
| With | 87.9 | 89.4 | ||||||
| Without | 53.3 | 67.7 | ||||||
| Age (years) | 0.628 | 0.550 | ||||||
| < 60 | 72.0 | 79.6 | ||||||
| ≥60 | 47.8 | 69.6 | ||||||
| CA-125 (U/mL) | 0.001 | 0.620 | 0.142 | |||||
| < 200 | 76.6 | 80.0 | ||||||
| ≥200 | 38.4 | 64.4 | ||||||
| Parity | 0.342 | 0.382 | ||||||
| 0 | 70.8 | 89.5 | ||||||
| ≥1 | 53.6 | 75.9 | ||||||
| Laterality | 0.034 | 0.093 | 0.028 | 0.360 | ||||
| Unilateral | 70.1 | 79.3 | ||||||
| Bilateral | 46.7 | 56.2 | ||||||
| Tumor diameter | 0.084 | 0.662 | 0.236 | |||||
| < 10 | 77.7 | 83.4 | ||||||
| ≥10 | 59.8 | 70.0 | ||||||
| Comprehensive staging | 0.348 | 0.070 | 0.441 | |||||
| Yes | 68.6 | 79.0 | ||||||
| No | 58.9 | 56.2 | ||||||
| Residual lesion | 0.000 | 0.126 | 0.001 | 0.731 | ||||
| Yes | 72.8 | 82.6 | ||||||
| No | 25.0 | 33.3 | ||||||
| Ascites | 0.000 | 0.016 | 0.001 | 0.052 | ||||
| Yes | 45.9 | 2.78 (1.21–6.47) | 60.8 | |||||
| No | 82.0 | 87.6 | ||||||
| Lymph nodes status | 0.000 | 0.324 | 0.012 | 0.395 | ||||
| Positive | 33.3 | 58.3 | ||||||
| Negative | 76.0 | 85.6 | ||||||
| FIGO stage | 0.000 | 0.033 | 1.61 (1.04–2.49) | 0.000 | 0.874 | |||
| I | 88.8 | 89.9 | ||||||
| II | 55.6 | 80.2 | ||||||
| III | 22.4 | 45.5 | ||||||
| IV | 33.3 | 33.3 | ||||||
| Chemotherapy cycles | 0.050 | 0.290 | 0.421 | |||||
| ≥6 | 72.5 | 78.4 | ||||||
| > 6 | 49.9 | 69.5 | ||||||
| Chemosensitivity | 0.000 | 0.000 | 101.60 (29.45–350.49) | 0.000 | 0.000 | 109.55 | ||
| Sensitive | 87.3 | 96.5 | (23.46–511.51) | |||||
| Resistant | 0 | 9.2 |
alog-rank test; b Cox-proportional hazards model